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Abstract 
Background: Immunosuppressive therapy (IT) such as tacrolimus are influenced by p-
glycoprotein (P-gp) which modulates cellular efflux of this drug. P-gp is present on peripheral 
mononuclear cells (PBMC) and is encoded by the ABCB1 gene. No data are available 
regarding the impact of race on ABCB1 gene expression in PBMCs post-transplant over IT 
dosing interval. 
Methods: An observational study was completed in 20 African American (AA) and 11 
Caucasian (C) stable renal transplant recipients (RTR) (ages 30-74 yrs) receiving tacrolimus 
(trough: 5 - 10 ng /ml), and enteric coated mycophenolate sodium. At time 0 (prior to IT) & 4, 8 
and 12 hours after immunosuppression, PBMCs were collected for ABCB1 gene expression 
analysis by quantitative real-time-polymerase chain reaction (QRT-PCR). The target ABCB1 
gene PCR product was cloned, and verified by sequencing. The cloned ABCB1 gene was used 
to establish standard curves (linear over 6 orders of magnitude; r 2=0.996) and assess PCR 
efficiencies. Total ABCB1 copies and normalized copies using Alien RNA were assessed. 
Results: The normalized (p<0.0006) and non-normalized (p< 0.0001) ABCB1 gene expression 
was higher among Caucasians and at each time until 12 hours. See Table below.  
Conclusions: The racial differences in ABCB1 gene expression was noted with greater 
expression in Caucasians than African Americans. These racial differences in ABCB1 gene 
expression may influence intracellular tacrolimus concentrations mediated by P-gp and affect 
clinical outcomes relative to African Americans and Caucasians 
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Results 
 
 
 
 
RNA Isolation and cDNA synthesis:  
Total RNA was isolated from 200 uL of PBMC as per manufacturers’ protocols (Qiagen, Valencia, CA). First 
strand cDNA was synthesized in a 50 uL reaction containing 1 uL oligo (dT12-18 at 500 g/uL), 2 uL Alien® RNA 
control as internal standard (5x108 Copies/uL), and 30 uL total RNA (100 ng of total RNA), and 1uL 
StrataScript™ reverse transcriptase (50 U/uL) for reverse transcription process. 
 
Quantitative real-time PCR:   
MRP2 gene expression was determined using 25 uL reaction volume containing 12.5   uL RT2 SYBR 
Green/ROX qPCR master mix (SuperArray®, California, USA), 10.5    ddH2O, 1 uL template cDNA, and 1 uL 
MRP2 gene specific 10 uM PCR primer pair stock.  The PCR reactions were initiated with denaturation at 95 ºC 
for 10 minutes, followed 40 cycles of amplification at 95 ºC for 15 seconds, and annealing at 60 ºC for 
60  seconds.  The PCR cycles were followed by a dissociation curve analysis to confirm the single   PCR product 
(verified by gel analysis).  
 
QRT-PCR standard curves and target verification:   
The PCR product was cloned into a plasmid vector (pCR2.1-TOPO) using the TOPOTM TA Cloning kit and 
sequenced to verify as MRP2.  Cloned PCR product was utilized to establish standard curves of known 
concentrations for absolute quantitation of MRP2 gene expression levels and to assess efficiency of each PCR 
run.  Each sample was analyzed in triplicate.   
Normalization:   
To correct for experimental errors, samples were normalized using QRT-PCR data based upon Alien® primers. 
 
 Statistical Analysis:  
Repeated measures ANOVA was utilized to evaluate differences as follows: 
•  Timed differences between race  at time 0 hours (trough) 
•  Timed differences between race  at times 4, 8 and 12 hours  
•   ANOVA was used to determine difference between Caucasian female and male patients 
 
Study Design: An open-label, single center observational PK-pharmacogenomic study in 20 African 
American and 11 Caucasian male RTR who were clinically stable receiving oral immunosuppression: 
tacrolimus (Prograf), enteric coated mycophenolate sodium (EC-MPS)  for >6 months was completed. 
  
Study Day Procedure: 
Methods 
Introduction 
• Immunosuppressive agents such as cyclosporine and tacrolimus are substrates for P-
glycoprotein (P-gp) efflux transporters. 
 
• These drugs elicit their respective pharmacologic mechanism by intracellular action within the 
activated lymphocytes to prevent graft rejection. (See Figure 1) 
 
• Since T lymphocytes express P-gp, alterations in P-gp expression may modify the overall 
pharmacologic effects from these immunosuppressive agents in the transplant recipient. 
 
• Increased expression of ABCB1 (MDR1) in lymphocytes, which encodes for P-gp, may be 
associated  with resistance to immunosuppression and development of graft rejection. 
 
• In addition, African Americans have been described to have single nucleotide polymorphisms 
of ABCB1 compared to Caucasians which may reduce the pharmacologic response to 
immunosuppressive agents and subsequent graft survival.  
 
• Our research group has demonstrated  time dependent change in ABCB1 expression  in 
PBMCs in relation to I cyclosporine drug  therapy (Tornatore et al,; Clin. Pharmacol.Ther.  
2007:81:2). 
•  However, it is unclear to date if the  ABCB1 expression changes in relation to race or gender. 
 
 
 
 
 
 
 
 
• Patients were admitted to the Clinical Research Center at 7AM after an overnight fast and an 
IV angiocatheter was inserted. 
 
• Time zero blood samples were collected using Cell Preparation Tubes (CPT®) followed by  
administration of oral  tacrolimus with other immunosuppressive drugs. Food and other 
medications were given after 2  hours. 
 
• Whole blood samples were collected 4,8, and 12  hours post-dose. 
 
• Blood samples for MDR-1 gene expression were collected at baseline (Time 0) and 4 , 8 and 
12 hours post oral immunosuppression in Cell Preparation Tubes with sodium citrate (CPT®- 
BD Vacutainer). Plasma was aspirated and peripheral mononuclear  cells (PBMCs) were 
harvested immediately; frozen in liquid nitrogen and stored at -70ºC until Q-PCR analysis. 
 
 
 
 
Study Objectives 
 
• To conduct a study to quantitate MDR1(ABCB1) gene expression  from peripheral blood 
mononuclear cells (PBMCs)  prior to (trough of immunosuppressive drug) compared to 
4, 8 and 12 hours after administration of immunosuppressive regimen of Tacrolimus and 
Mycophenolic  Acid in relation to race and  time within the dosing interval. 
Patient Demographics 
Extracellular    Drug 
Concentration  
(Immunosuppressive    
Drugs A,B,C)
Hepatic
Metabolism
Combination Drug Regimen 
Administered to patient 
( Drugs A,B, & C)
GI Tract
Total Drugs
A,B,C
Drug 
Exposure
( AUC)
Free 
Drugs
T Helper
Lymphocyte
P-gp
Efflux
Proteins
IL-2
Receptor
(CD25)
CD4+  
Receptor
P-gp
Efflux 
Protein
Free 
Drugs
TH1 vs TH2
Intracellular
mechanism
of action
of drugs
CYP 
3A
CYP
3A
Adverse 
Drug 
Effects
Immunosuppressive
drug de-toxification
Renal 
Allograft
Pharmacologic Immunosuppression
T Cytotoxic
Lymphocyte
CD8+
Receptor
IL-2 
Receptor 
(CD25)
Excessive Drug 
Exposure
P-gp
Efflux 
Protein
IL-2
SIL-2R
Figure 1: 
•  The normalized (p<0.0006) and non-normalized (p< 0.0001) ABCB1 gene expression  in PBMCs was  
 higher among Caucasians and at each time until 12 hours.  
                                                                 Conclusions 
• The racial differences in ABCB1 gene expression was noted with greater expression in Caucasians than    
 African Americans.  
•      These racial differences in ABCB1 gene expression may influence intracellular tacrolimus 
 concentrations  mediated by P-gp and affect clinical outcomes relative to African Americans and 
 Caucasians  
 
Summary 
ABCB1 Copies x 
106 Total RNA 
 
0 Hours 
 
4 Hours 
 
8 hours 
 
12 Hours 
African 
Americans 
28.0 ± 14.6 25.0 ± 16.8  26 ± 15.2 33.4 ± 24.7 
Caucasians 61.1 ± 46.3  57.2 ± 48.6 56.5 ± 47.8 53.8 ± 24.2 
Post hoc Pair-
wise 
p values 
 
0.003 
 
0.004 
 
0.006 
 
0.08 
Demographics 
Mean ± SD 
African Americans 
(N=20) 
Caucasians (N=11) P Value (NS: Non-
significant) 
AGE (years) 48 ± 13 51 ± 11 NS 
Est. GFR (ml/min) 57.5 ± 13.9 62.6 ± 19.5 NS 
Tacrolimus Trough 
(ng/ml) 
7.4 ± 2.2 7.3 ± 1.3 NS 
Mycophenolic Acid 
Trough (mg/dL) 
4.2 ± 3.3 5.8 ± 5.6 NS 
Mycophenolate 
Glucuronate (mg/dL) 
46.0 ± 31.9 41.4 ± 31.9 NS 
Time Post-Transplant 
(Mos) 
28.9 ± 21.5 58.8 ± 53.8 NS 
Diabetes 30% 10% NS 
